News | September 23, 2008

Perkinelmer Expands NEN® Radiochemical Product Portfolio

PerkinElmer, a global leader in life science research, drug discovery and cellular science, recently announced that it has expanded its 125I-iodinated radiochemical ligand product line, adding 26 new labeled compounds.

The expanded product line increases the number of ligands currently available to scientists involved in cutting-edge disease state research, enabling them to expand their research and drug development efforts. The radioligands allow scientists to characterize membrane receptors for affinity, specificity and kinetics. Identifying and characterizing receptors is an important step in drug discovery. PerkinElmer provides the broadest line of these most basic tools needed for the advancement of drug development.

"Radiochemicals remain the reagent standard for a wide range of research applications based on their superior sensitivity, time-to-results and ease-of-use," said Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer. "PerkinElmer recognizes that all of its customers have a choice in radiochemical suppliers, and is therefore committed to continually enhancing our level of service to new and existing customers through ongoing investments in new product development, customer support and production capacity."

The 26 new compounds include:

  • ACTH (1-39) 2 Tyr, [125I]
  • ACTH (1-39) 23 Tyr, [125I]
  • Adrenomedulin (Rat), [125I]
  • Amyloid 1-40, [125I]
  • Atrial Natriuretic Factor (Rat), [125I]
  • Atrial Natriuretic Peptide (Human), [125I]
  • Bungarotoxin, [125I] High Specific Activity
  • Calcitonin Tyr 12 (Human), [125I]
  • Calcitonin Tyr 22 (Salmon), [125I]
  • Corticotropin Releasing Factor, [125I]
  • Cortisol, [125I125]
  • Dendrotoxin, [125I]
  • Deoxyuridine, [125I]-Iodo-2'
  • Echistatin, [125I]
  • Epidermal Growth Factor, [125I]
  • Fribrinogen (Human), [125125I]
  • Gastrin Releasing Peptide (Porcine) 15 Tyr, [125I]
  • Insulin (Human Recombinant), [125I]
  • Insulin-like Growth Factor 2 (Human Recombinant), [125I]
  • Iodoaminopotentidine, [125I]
  • Nerve Growth Factor (Murine), [125I]
  • Nerve Growth Factor (Human Recombinant), [125I]
  • Neuropeptide Y (Porcine), [125I]
  • Oestradiol, [125I]
  • PDGF, [125I]
  • SB258585, [125I]

PerkinElmer provides more than 600 NEN-branded radioactive nucleotides, ligands and amino acids to the global scientific community. The Company plans continued expansion of its NEN radiochemical portfolio and offers an extensive line of readers, liquid scintillation counters and other high-performance instrumentation that enable customers to create complete radiochemical application solutions.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8B in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com.

SOURCE: PerkinElmer, Inc.